The EPS projection of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for quarter ended 2016-09-30 is $-0.2. Last week, the projection for EPS was $-0.2 against target of $-0.2, a month earlier. While 2-months ago, this projection was $-0.2 versus forecast of $-0.2a quarter months earlier, posting a deviation of 0%.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) posted that 18 days earlier, the share price was revised 1 times on upside. In addition, negative revisions were 0.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 2, and 2, correspondingly.
The per-share earnings downgrade for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the preceding 30 and 120 were 0 and 2. While in 60 and 90 days were 0, and 2, in that order.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) EPS target was $-0.2 for the quarter closed 1. It was based on 7 calls. As on 2016-05-05 the EPS was $-0.31. The change was $-0.08, posting a deviation of -34.78%. The price projections gave a standard deviation of 0.01.
Quarterly Sales Estimates
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) sales prediction for the fiscal 2016 stands at $5.163 and the median estimate is at $4.974. Almost 4 analysts gave sales target.
Among this, the highest sales estimate is $6.484 while the lowest target is $4.22 showing standard deviation of 0.986%.
As many as 4 analysts have positive sales targets revision while 4 reduced sales estimates, posting a deviation of 0%.
Last month, 4 experts have positive sales number revision. Also, 4 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 4 hiked sales target and 4 reduced sales forecast, posting a deviation of -16.98%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...